Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Important post by a Biostatistician
rashedul...
I send the following email to them about their wrong misleading PR:

We are awaiting for the Phase 2 results and we got that. After checking the update, I was shocked as I am a Biostatistician. Your PR team and Biostat team did a poor job! You should not keep them to uphold investors rights.

Let me calculate the math for you. In Clinical RCT studies, all we care about is the relative change between Treatment (Abivertinib) and Control.

In the US Phase II study (n=96), your improvement (survival at 1 month) was 78.3% for Abivertinib vs. 58.3% for Control. You wrote 20% improvement (?). How? Respect to what? Actually, what you should report is the relative improvement for Abivertinib compared to Control which is 78.3/58.3 = 1.343 implying Abivertinib brought (1.343-1) =34.3% more improvement (survival at 1 month) when compared to Control! HUGE clinical result! Each 1 of 3 deaths could be averted if Abivertinib is used! And you wrote merely 20%? You should interpret it properly.

Similarly, for Brazil study (n=400), the results are better. Mind blowing! The relative improvement there was 69.6/44.4 = 1.568 implying Abivertinib brought (1.568-1) =56.8% more improvement (survival at 1 month) when compared to Control!but you report 25%? Why? Around 6 out of 10 such deaths could be averted by using Abivertinibis! This is a result the whole world is looking for!!

Clinically and statistically, the results make total sense. Large sample (n=400) gives a larger effect size. And, more confident breakthrough results!! You should definitely work with your PR and Stats team. As a Biostatistician, I can also help you. I am doing those works regularly!

And we investors are taking the hit because of those poor PR jobs!!

Please read this and take actions accordingly.